← Leaderboards
Sara Isabel Pai
Massachusetts General Hospital
$12,404,338
Attributed
$13,715,606
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,071,933 · 12
FDA$1,058,315 · 1
By mechanism
P01$10,950,292 · 5
R01$6,344,986 · 4
P50$2,391,256 · 2
U01$2,056,129 · 1
R21$387,585 · 1
Top collaborators
- Ralph Weissleder5 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Gary B. Ruvkun$40,968,557
- Liron Bar-Peled$4,230,233
- Basak Elif Uygun$2,902,127
- Leif W Ellisen$14,503,955
- Mingming Ning$8,518,949
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneHead And Neck Squamous Cell CarcinomaTumorHead And Neck CancerResponseTranslatingCellsMalignant NeoplasmsProgramsBiopsyImmune ResistanceClinical TrialsBiopsy SpecimenImmunotherapeutic AgentInnovationImmunotherapyPeptidesTissuesCancer CellT-LymphocyteIn VivoStainsImmune ResponseCombinatorial
Grant awards (41)
Early detection and risk of head and neck cancer through immune based spatial omics$677,643
U01 · FY2025 · DE · contact PI
Cue-101 and TCR-T cell Combinatorial Strategy for HPV+ Head and Neck Cancers$675,007
R01 · FY2025 · CA · contact PI
Cue-101 and TCR-T cell Combinatorial Strategy for HPV+ Head and Neck Cancers$691,530
R01 · FY2024 · CA · contact PI
Early detection and risk of head and neck cancer through immune based spatial omics$673,156
U01 · FY2024 · DE · contact PI
FAST-FNA immune cell profiling in HNSCC$637,189
R01 · FY2024 · CA
Strategies to Overcome Immune Resistance in Head and Neck Cancers$1,411,624
P01 · FY2023 · CA · contact PI
Early detection and risk of head and neck cancer through immune based spatial omics$705,328
U01 · FY2023 · DE · contact PI
FAST-FNA immune cell profiling in HNSCC$657,310
R01 · FY2023 · CA
Project 1:Therapeutically improving HNSCC antigenicity through epigenetic reprogramming$268,727
P01 · FY2023 · CA · contact PI
Head and Neck Cancer Immunology Administrative Core$112,121
P01 · FY2023 · CA · contact PI
Early detection and risk of head and neck cancer through immune based spatial omics$2
U01 · FY2023 · DE · contact PI
Strategies to Overcome Immune Resistance in Head and Neck Cancers$1,702,538
P01 · FY2022 · CA · contact PI
FAST-FNA immune cell profiling in HNSCC$657,310
R01 · FY2022 · CA
Project 1:Therapeutically improving HNSCC antigenicity through epigenetic reprogramming$400,078
P01 · FY2022 · CA · contact PI
Head and Neck Cancer Immunology Administrative Core$125,117
P01 · FY2022 · CA · contact PI
Strategies to Overcome Immune Resistance in Head and Neck Cancers$1,747,687
P01 · FY2021 · CA · contact PI
FAST-FNA immune cell profiling in HNSCC$670,725
R01 · FY2021 · CA
Project 1:Therapeutically improving HNSCC antigenicity through epigenetic reprogramming$408,242
P01 · FY2021 · CA · contact PI
Phase II Trial of Anti-PD1 Therapy for HPV-associated Recurrent Respiratory Papillomatosis (IND#128874)$299,151
R01 · FY2021 · FD · contact PI
Head and Neck Cancer Immunology Administrative Core$133,511
P01 · FY2021 · CA · contact PI
Strategies to Overcome Immune Resistance in Head and Neck Cancers$1,766,471
P01 · FY2020 · CA · contact PI
Project 1:Therapeutically improving HNSCC antigenicity through epigenetic reprogramming$408,242
P01 · FY2020 · CA · contact PI
Phase II Trial of Anti-PD1 Therapy for HPV-associated Recurrent Respiratory Papillomatosis (IND#128874)$343,904
R01 · FY2020 · FD · contact PI
Head and Neck Cancer Immunology Administrative Core$135,290
P01 · FY2020 · CA · contact PI
Phase II Trial of Anti-PD1 Therapy for HPV-associated Recurrent Respiratory Papillomatosis (IND#128874)$55,000
R01 · FY2020 · FD · contact PI
Strategies to Overcome Immune Resistance in Head and Neck Cancers$1,786,322
P01 · FY2019 · CA · contact PI
Project 1:Therapeutically improving HNSCC antigenicity through epigenetic reprogramming$408,242
P01 · FY2019 · CA · contact PI
Phase II Trial of Anti-PD1 Therapy for HPV-associated Recurrent Respiratory Papillomatosis (IND#128874)$360,260
R01 · FY2019 · FD · contact PI
Head and Neck Cancer Immunology Administrative Core$136,080
P01 · FY2019 · CA · contact PI
Immune Checkpoints and HPV-associated Head and Neck Cancers$435,000
R01 · FY2017 · DE · contact PI
Immune Checkpoints and HPV-associated Head and Neck Cancers$431,300
R01 · FY2016 · DE · contact PI
Immune Checkpoints and HPV-associated Head and Neck Cancers$431,300
R01 · FY2015 · DE · contact PI
Oral Biomarkers for HPV-related Head and Neck Cancer$176,175
R21 · FY2014 · CA · contact PI
HPV Vaccine and Correlates of Response$341,958
P50 · FY2013 · DE · contact PI
Oral Biomarkers for HPV-related Head and Neck Cancer$211,410
R21 · FY2013 · CA · contact PI
HPV Vaccine and Correlates of Response$294,944
P50 · FY2012 · DE · contact PI
HPV VACCINE THERAPY AND CORRELATES OF RESPONSE IN HEAD AND NECK SQUAMOUS CELL$360,801
P50 · FY2011 · DE · contact PI
HPV VACCINE THERAPY AND CORRELATES OF RESPONSE IN HEAD AND NECK SQUAMOUS CELL$372,060
P50 · FY2010 · DE · contact PI
HPV VACCINE THERAPY AND CORRELATES OF RESPONSE IN HEAD AND NECK SQUAMOUS CELL$361,302
P50 · FY2009 · DE · contact PI
HPV VACCINE THERAPY AND CORRELATES OF RESPONSE IN HEAD AND NECK SQUAMOUS CELL$352,657
P50 · FY2008 · DE · contact PI
HPV VACCINE THERAPY AND CORRELATES OF RESPONSE IN HEAD AND NECK SQUAMOUS CELL$307,534
P50 · FY2007 · DE · contact PI